PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Developing Alternative Solutions in Health-Boosting Market
- Company offers options to patients seeking immune system-boosting alternatives
- Novel “scorpion venom” product builds on popular Cuban cancer-fighting therapy
- Developing a CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures and neurological disorders
In an era when a licensed and regulated medical industry provides a secure standard of care for treating ailments but “complementary” or alternative therapies are sought by a number of patients — more than three out of 10 adults, according to the National Institutes of Health’s most recent survey on the subject (http://nnw.fm/L7uE5) — PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is offering patients novel choices in how to better the quality of their lives. PreveCeutical Medical is dedicated to proactive thinking in personal health management amid a growing market for preventive care, but, when things go wrong and clinical solutions aren’t readily available, the company also wants to help find alternatives that result from the best products nature and science can cooperatively deliver. The early-stage life sciences company has brought one product to market, a solution derived from Caribbean blue scorpion venom, and it is pursuing five other research projects under its product development program.
“We are encouraged from the fact that the Caribbean Blue Scorpion venom peptides bypasses the blood brain barrier and attaches to the abnormal cells, this is an indicator that we are going in the right direction,” PreveCeutical CEO Stephen Van Deventer stated in a news release last August (http://nnw.fm/WvCe2) announcing the company’s partnership with Sports 1 Marketing (S1M) to develop the scorpion venom as a treatment for concussions, or mild traumatic brain injury, among athletes.
The scorpion venom product builds on discoveries in Cuba and the surrounding Caribbean nations advancing the popular belief that the venom inhibits the growth of cancer cells. PreveCeutical’s product, CELLB9Ò dietary supplement, utilizes select peptides from the blue scorpion (which is actually red, with a blue tail) to boost the user’s immune system, and the company is advancing its research into producing a “nature identical” scorpion peptide solution that it hopes will be able to not only halt the progress of cancerous tumors, but also treat metabolic disorders, pain, cardiovascular disease and infectious maladies without requiring company representatives to travel to the Caribbean to find and milk the unique scorpions for their naturally produced venom.
The company is also working on a medical cannabis gel formulated drug delivery system to deliver relief from ailments such as pain, inflammation, seizures and neurological disorders via nasal administration that potentially avoids side effects that might accompany the digestion of cannabidiol through the gastrointestinal system. The proprietary “Sol-gel” research and development program is being conducted in Brisbane, Australia, and, in November, PreveCeutical received approval from the Queensland state government to acquire, store and use high-quality dried cannabis plant extracts through its partnership with UniQuest Pty Limited at the University of Queensland (http://nnw.fm/2gNFp). Once an importation permit is acquired, PreveCeutical can begin shipping cannabis from its Canadian-licensed producer.
Another initiative with a longer development schedule involves finding a therapy to treat obesity and diabetes by targeting an overactive gene common to both ailments. The company is searching for a breakthrough on non-addictive analgesics as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone.
On January 15, PreveCeutical announced its place in the blockchain fintech revolution by accepting bitcoin as a payment option for CELLB9Ò (http://nnw.fm/Qu8bc). Despite stock fluctuations during the past month, the bitcoin cryptocurrency remains popular with individuals who conduct commerce on a global scale and who seek a seamless transaction process that doesn’t require fees or other potential obstacles that may arise from using third-party banks. PreveCeutical made the decision after receiving requests from several customers.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Company offers options to patients seeking immune system-boosting alternatives
- Novel “scorpion venom” product builds on popular Cuban cancer-fighting therapy
- Developing a CBD-based nose-to-brain delivery system that will provide relief across a range of indications from pain, inflammation, seizures and neurological disorders
In an era when a licensed and regulated medical industry provides a secure standard of care for treating ailments but “complementary” or alternative therapies are sought by a number of patients — more than three out of 10 adults, according to the National Institutes of Health’s most recent survey on the subject (http://nnw.fm/L7uE5) — PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) is offering patients novel choices in how to better the quality of their lives. PreveCeutical Medical is dedicated to proactive thinking in personal health management amid a growing market for preventive care, but, when things go wrong and clinical solutions aren’t readily available, the company also wants to help find alternatives that result from the best products nature and science can cooperatively deliver. The early-stage life sciences company has brought one product to market, a solution derived from Caribbean blue scorpion venom, and it is pursuing five other research projects under its product development program.
“We are encouraged from the fact that the Caribbean Blue Scorpion venom peptides bypasses the blood brain barrier and attaches to the abnormal cells, this is an indicator that we are going in the right direction,” PreveCeutical CEO Stephen Van Deventer stated in a news release last August (http://nnw.fm/WvCe2) announcing the company’s partnership with Sports 1 Marketing (S1M) to develop the scorpion venom as a treatment for concussions, or mild traumatic brain injury, among athletes.
The scorpion venom product builds on discoveries in Cuba and the surrounding Caribbean nations advancing the popular belief that the venom inhibits the growth of cancer cells. PreveCeutical’s product, CELLB9Ò dietary supplement, utilizes select peptides from the blue scorpion (which is actually red, with a blue tail) to boost the user’s immune system, and the company is advancing its research into producing a “nature identical” scorpion peptide solution that it hopes will be able to not only halt the progress of cancerous tumors, but also treat metabolic disorders, pain, cardiovascular disease and infectious maladies without requiring company representatives to travel to the Caribbean to find and milk the unique scorpions for their naturally produced venom.
The company is also working on a medical cannabis gel formulated drug delivery system to deliver relief from ailments such as pain, inflammation, seizures and neurological disorders via nasal administration that potentially avoids side effects that might accompany the digestion of cannabidiol through the gastrointestinal system. The proprietary “Sol-gel” research and development program is being conducted in Brisbane, Australia, and, in November, PreveCeutical received approval from the Queensland state government to acquire, store and use high-quality dried cannabis plant extracts through its partnership with UniQuest Pty Limited at the University of Queensland (http://nnw.fm/2gNFp). Once an importation permit is acquired, PreveCeutical can begin shipping cannabis from its Canadian-licensed producer.
Another initiative with a longer development schedule involves finding a therapy to treat obesity and diabetes by targeting an overactive gene common to both ailments. The company is searching for a breakthrough on non-addictive analgesics as a replacement to highly addictive analgesics such as morphine, fentanyl and oxycodone.
On January 15, PreveCeutical announced its place in the blockchain fintech revolution by accepting bitcoin as a payment option for CELLB9Ò (http://nnw.fm/Qu8bc). Despite stock fluctuations during the past month, the bitcoin cryptocurrency remains popular with individuals who conduct commerce on a global scale and who seek a seamless transaction process that doesn’t require fees or other potential obstacles that may arise from using third-party banks. PreveCeutical made the decision after receiving requests from several customers.
For more information, visit the company’s website at www.PreveCeutical.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
